Zealand Pharma Announces GetGoal Duo 1 and GetGoal-L Phase III Data on Lixisenatide (Lyxumia(R))1 to be Presented at American Diabetes Association

COPENHAGEN, June 9, 2012 (GLOBE NEWSWIRE) -- Zealand Pharma A/S (Copenhagen:ZEAL) informs that its partner Sanofi (EURONEXT:SAN) (NYSE:SNY) today announced the presentation of further data from the GetGoal Duo 12 and GetGoal-L3 Phase III studies with lixisenatide, an investigational once-daily GLP-1 agonist discovered by Zealand Pharma and licensed to Sanofi for the treatment of Type 2 diabetes. The data were presented at the ADA’s 72th Annual Scientific sessions, taking place on 9 - 12 June 2012 in Philadelphia, Pennsylvania, USA.